<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753803</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_DIP_I</org_study_id>
    <nct_id>NCT02753803</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg</brief_title>
  <official_title>A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, multiple dosing, three-way crossover clinical trial to investigate
      the pharmacokinetic/pharmacodynamic drug-drug interaction of evogliptin 5 mg and pioglitazone
      30 mg after oral administration in healthy male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence,
      crossover study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2016</start_date>
  <completion_date type="Actual">March 10, 2017</completion_date>
  <primary_completion_date type="Actual">October 19, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>1d~6d pre-dose, 15d~20d pre-dose, 29~34d pre-dose, 7d/21d/35d pre-dose and post-dose</time_frame>
    <description>area under the concentration-time curve</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>A group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evogliptin Pioglitazone Evogliptin+Pioglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pioglitazone Evogliptin Evogliptin+Pioglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evogliptin Evogliptin+Pioglitazone Pioglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pioglitazone Evogliptin+Pioglitazone Evogliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evogliptin+Pioglitazone Evogliptin Pioglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evogliptin+Pioglitazone Pioglitazone Evogliptin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin, Pioglitazone, Evogliptin+Pioglitazone</intervention_name>
    <description>Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD</description>
    <arm_group_label>A group</arm_group_label>
    <other_name>Suganon</other_name>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone, Evogliptin, Evogliptin+Pioglitazone</intervention_name>
    <description>Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD</description>
    <arm_group_label>B group</arm_group_label>
    <other_name>Suganon</other_name>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin, Evogliptin+Pioglitazone, Pioglitazone</intervention_name>
    <description>Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD</description>
    <arm_group_label>C group</arm_group_label>
    <other_name>Suganon</other_name>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone, Evogliptin+Pioglitazone, Evogliptin</intervention_name>
    <description>Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD</description>
    <arm_group_label>D group</arm_group_label>
    <other_name>Suganon</other_name>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin+Pioglitazone, Evogliptin, Pioglitazone</intervention_name>
    <description>Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD</description>
    <arm_group_label>E group</arm_group_label>
    <other_name>Suganon</other_name>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin+Pioglitazone, Pioglitazone, Evogliptin</intervention_name>
    <description>Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD</description>
    <arm_group_label>F group</arm_group_label>
    <other_name>Suganon</other_name>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male Volunteers (Age: 19~45years)

          -  55&lt;Body Weight&lt;90, 18&lt;BMI&lt;27

          -  FPG: 70-125 mg/dL

        Exclusion Criteria:

          -  galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption

          -  Clinically significant Medical History

          -  Allergy or Drug Hypersensitivity

          -  AST(SGOT), ALT(SGPT) &gt; Upper Normal Range*1.5, eGFR&lt;80 mL/min

          -  Drink during clinical trial period

          -  Smoking during clinical trial period

          -  Grapefruit/Caffeine intake during clinical trial period

          -  No Contraception
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials Center, Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trials Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

